Topiramate enhances gamma-amino-butyric acid effects, has antiglutaminergic effects, and is a state-dependent sodium channel blocker.
Topiramate enhances gamma-amino-butyric acid effects, has antiglutaminergic effects, and is a state-dependent sodium channel blocker. 1 It is registered as an adjunctive treatment for epilepsy but is not registered for psychiatric indications. Nevertheless, it may be useful beyond its initial indication, considering the promising literature on which I report below. However, much more research evidence is needed to establish sufficient scientific justification for prescribing it routinely for psychiatric purposes.
Eating disorders
Three randomised, double-blind, placebo-controlled studies on the use of topiramate for bulimia nervosa have been undertaken. [2] [3] [4] All reported promising reductions in binging and purging behaviour, as well as body mass. One study specifically reported an improvement in body image, eating attitudes, anxiety and selfesteem. 3 Treatment was phased in at 25 mg per day, and increased where necessary to up to 400 mg per day. Topiramate appears to have been well tolerated but was discontinued in a small minority of subjects owing to side-effects. These studies were of relatively short duration (10 weeks) on relatively small numbers of subjects (60 -70). Barbee reported 5 cases of severe bulimia nervosa with co-morbid mood and/or anxiety disorders. promising results regarding weight loss in the treatment of obese patients suffering from major depressive disorder. 10 The results were less convincing regarding depression, and the investigators were concerned about central nervous system (CNS) side-effects.
A case was reported of a woman suffering from anorexia nervosa and epilepsy, whose epilepsy was treated with topiramate. After topiramate was started, the anorexia nervosa flared up again.
The authors concluded that it might have been precipitated by topiramate. Roy Chengappa et al. 13 performed a randomised, double-blind, placebo-controlled trial to assess the efficacy of topiramate as an adjunctive treatment in adults with bipolar I disorder. Although topiramate turned out to be an inefficacious adjunctive treatment, significant weight loss was found when compared with placebo.
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Obesity/weight gain
Although the literature clearly indicates that weight loss can occur on topiramate, it is not registered for that purpose; neither did I find any practice guidelines in this regard.
Weight loss on topiramate has also been described in children suffering from bipolar disorder who gained weight due to psychotropic treatment. The study was small (10 subjects), relatively brief (11 weeks) and had an open-label design. 21 In both of these case studies, topiramate appeared to improve the alcohol abuse.
20,21
Smoking
Johnson et al. 22 extended their above-mentioned study 17 to investigate the effect of topiramate on cigarette smoking. They used a double-blind, placebo-controlled design involving 94 subjects over a 12-week period. They concluded that topiramate showed potential for the treatment of cigarette smoking in alcoholdependent individuals. Khazaal et al. 23 reported on a small number (13) of cigarette smokers who were given topiramate in an open-label trial. After 2 months, 6 of them were abstinent, 3
had a temporary reduction in smoking, and 3 could not tolerate topiramate.
Cocaine
Kampman et al. 24 described a 13-week, double-blind, placebocontrolled trial with topiramate as the active medication for the treatment of 40 subjects diagnosed with cocaine dependence.
The results indicated that the topiramate-treated subjects were more likely to abstain from cocaine than the placebo-treated subjects. The authors came to the conclusion that topiramate might be effective for the treatment of cocaine dependence.
Borderline personality disorder
Relatively small and brief randomised, placebo-controlled studies indicate that topiramate may be useful for treating borderline personality disorder (BPD) at dosages of 200 mg per day (that were titrated upwards from 25 mg per day). Loew et al. 25 studied 56 patients over a 10-week period with promising results.
Nickel et al. 26 studied 29 women with BPD and found significant reductions in anger measurements. Nickel et al. 27 repeated the study with 42 male subjects suffering from BPD, with similar results.
In both the Nickel et al. studies, the dosages were 250 mg per day after titration upwards from 50 mg per day.
Do Prado-Lima et al. 28 reported a case study of a woman with BPD who responded to topiramate. Cassano et al. 29 described a 24-year-old woman with bipolar II disorder and BPD who was treated with topiramate in the course of trying to find a drug that controlled her depression; self-mutilation ceased after 2 weeks on 200 mg per day, despite no improvement of her depression. After topiramate had been discontinued, self-mutilation recurred, but ceased again after re-introducing the topiramate.
Anger, aggression and self-injury
Gobbi et al. 30 reported on a retrospective, case-controlled, mirrorimage study involving 45 inpatients with marked aggression and agitation who were managed in a maximum-security Canadian psychiatric hospital. The patients were suffering from schizophrenia, schizo-affective disorder and bipolar disorder. 
Disorders of impulse control
In an open-label pilot study involving a small number of patients (14) for a relatively short period (16 weeks), Lochner et al. indicated that topiramate showed promise for use in trichotillomania. 35 They used a flexible dose of 50 -250 mg per day.
After a single-blinded 12-week study of 31 male subjects with a DSM-IV diagnosis of pathological gambling, the authors concluded that both topiramate and fluvoxamine may be effective in the treatment of pathological gambling. 36 This study was small and of relatively short duration. In a small case series of 3 kleptomanic patients, it was reported that subjects responded well to topiramate given either alone or in combination with an SSRI. 
Post-traumatic stress disorder
